|[October 08, 2013]
The Rosen Law Firm Announces Investigation of Securities Claims Against Atossa Genetics, Inc. --- ATOS
NEW YORK --(Business Wire)--
The Rosen Law Firm, P.A. announces that it is investigating potential
securities claims against Atossa Genetics, Inc. (NASDAQ:ATOS) resulting
from allegations that the company may have issued materially misleading
information about its business.
On October 4, 2013, after the close of trading, Atossa announced a
voluntary recall of its ForeCYTE Breast Health Test Mammary Aspiration
Specimen Cytology Test (MASCT). This voluntary recall includes the MASCT
System Kit and Patient Sample Kit. The voluntary recall was commenced to
address concerns raised in a February 2013 warning letter issued by the
U.S. Food and Drug Administration (the "FDA"). In its warning letter,
the FDA raised the following concerns: (1) the current instructions for
use (IFU); (2) ertain promotional claims used to market these devices;
and (3) the need for FDA clearance for certain changes made to the
Nipple Aspirate Fluid (NAF) specimen collection process identified in
the current IFU. Upon disclosure of this news, shares of Atossa fell
$2.47 per share or approximately 46% in trading on October 7, 2013 to
close at a price of $2.85 per share.
The Rosen Law Firm is preparing a class action lawsuit as a result of
this adverse information. If you purchased ATOS securities prior to
October 4, 2013, you may visit the website at http://www.rosenlegal.com
to join the action. You may also contact Phillip Kim, Esq. or Kevin
Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via e-mail
at firstname.lastname@example.org or email@example.com.
The Rosen Law Firm represents investors throughout the globe,
concentrating its practice in securities class actions and shareholder
Attorney Advertising. Prior results do not guarantee a similar outcome.
[ Back To Technology News's Homepage ]